CIBC Asset Management
BEAM icon

CIBC Asset Management’s Beam Therapeutics BEAM Stock Holding History

CIBC Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,741
Closed -$218K – 1528
2021
Q4 		$218K Buy
2,741
+223
+9% +$19.1K ﹤0.01% 1334
2021
Q3 		$219K Buy
2,518
+367
+17% +$36.9K ﹤0.01% 1286
2021
Q2 		$277K Buy
+2,151
New +$171K ﹤0.01% 1047

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Asset Management's BEAM Position: Q1 2022 in Review

CIBC Asset Management sold out of Beam Therapeutics (BEAM) in Q1 2022, closing a stake of 2,741 shares — an estimated $218K sold.

CIBC Asset Management first reported a position in BEAM in Q2 2021 and held it in 3 quarters. The position peaked at $277K in Q2 2021. 240 funds tracked by Wall St. Rank hold BEAM as of Q1 2022.

  • CIBC Asset Management reported no remaining Beam Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CIBC Asset Management sold 2,741 Beam Therapeutics shares in Q1 2022, an estimated $218K.
  • CIBC Asset Management first reported a position in Beam Therapeutics in Q2 2021 and held it in 3 quarters.
  • CIBC Asset Management's Beam Therapeutics position peaked at $277K in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2022.

Based on CIBC Asset Management's 13F filing for Q1 2022, filed 6 May 2022.